Mark Cobbold, Ph.D., M.B.Ch.B.

Associate Investigator
Cancer Center, Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Associate Member
Broad Institute
MBCHB University of Edinburgh 1995
PhD University of Birmingham-UK 2006
cancer; cancer immunotherapy; healthy immune response; immunity; t-cell activating biotherapeutics; tumor neoantigens The Cobbold laboratory focuses on understanding how the healthy human immune response is able to recognize and target cancerous cells, and when it fails, how it could be strengthened to recognize this endogenous threat. Our immune system faces a challenge in targeting cancerous cells as they are not “foreign” yet subtle changes in the cellular proteins exist that nevertheless allow our immune cells (T-cells) to detect them. Cancer cells modify internal proteins in different ways to healthy cells, a process fundamental to a cell becoming cancerous. These abnormal modifications can be recognized by T-cells and we believe play a role in protecting us against cancer.

In patients with cancer, this immunity is often lost and therefore new approaches may be needed. We are developing therapeutics that mobilize existing potent immune responses to instead tackle cancer. These immune-based therapies make cancerous cells appear virally infected in the hope that our own anti-viral immunity could step in to fill the void.
Research lab website Publications

CNY-Building #149
149 13th Street
Charlestown, MA 02129